Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Implementation for Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals Using Novel Regimen of Isoniazid/Rifapentine Daily (4 Weeks) Compared to Isoniazid/Rifapentine Weekly (12 Weeks)

NCT03785106 is registered in ClinicalTrials.gov with The HIV Netherlands Australia Thailand Research Collaboration as lead sponsor.

NCT NCT03785106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03785106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Implementation for Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals Using Novel Regimen of Isoniazid/Rifapentine Daily (4 Weeks) Compared to Isoniazid/Rifapentine Weekly (12 Weeks)
Lead sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 15, 2019
Completion date
March 31, 2038
Enrollment
2,500 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-infected participants with latent tb infection in high tb burden country